Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders... Show more
A.I.dvisor indicates that over the last year, DMRA has been closely correlated with COGT. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if DMRA jumps, then COGT could also see price increases.
| Ticker / NAME | Correlation To DMRA | 1D Price Change % | ||
|---|---|---|---|---|
| DMRA | 100% | +0.81% | ||
| COGT - DMRA | 75% Closely correlated | -0.96% | ||
| NERV - DMRA | 45% Loosely correlated | -4.35% | ||
| INBX - DMRA | 44% Loosely correlated | -5.11% | ||
| RANI - DMRA | 44% Loosely correlated | +1.86% | ||
| GNTA - DMRA | 38% Loosely correlated | -5.71% | ||
More | ||||
Industry Biotechnology
The RSI Oscillator for DMRA moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 26 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMRA as a result. In 74 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for DMRA just turned positive on October 07, 2026. Looking at past instances where DMRA's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.
Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMRA advanced for three days, in 205 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
DMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for DMRA moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for DMRA entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.400) is normal, around the industry mean (3.037). DMRA has a moderately low P/E Ratio (-81.769) as compared to the industry average of (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. DMRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.